Israel’s largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.

Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity.

When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of technology and biology, healthcare and data,” says Dr. Yair Schindel, its Managing Partner.

Through a new partnership, the National Institutes of Health will harness Israeli startup MDClone’s platform to generate computationally-derived synthetic data directly from clinical health data aggregated across the U.S., to underpin and advance research in the fight against COVID-19.

Curesponse, a cancer precision medicine company, has raised $6M from investors including NCL Technology Ventures (UK) and aMoon (Israel) for scaling clinical trials and international expansion to the UK.

Zebra Medical Vision, the deep-learning medical imaging analytics company, announces today its fifth FDA 510(k) clearance for its Vertebral Compression Fractures (VCF) product.

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.

Yair Schindel, aMoon Managing Partner and a member of Israel’s health ministry task force on COVID-19, spoke to the The New York Times about the pandemic and Israel’s latest initiative to conduct nationwide serological testing on 100,000 citizens. Yair outlined the two likely scenarios Israel might find out as a result of the antibody testing.

resTORbio, Inc. (Nasdaq: TORC) and Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications.